Bencini Lapo, Annecchiarico Mario, Farsi Marco, Bartolini Ilenia, Mirasolo Vita, Guerra Francesco, Coratti Andrea
Lapo Bencini, Mario Annecchiarico, Marco Farsi, Ilenia Bartolini, Vita Mirasolo, Francesco Guerra, Andrea Coratti, Department of Oncology, Division of Surgical Oncology and Robotics, Careggi University Hospital, 50131 Florence, Italy.
World J Gastrointest Oncol. 2015 Dec 15;7(12):411-21. doi: 10.4251/wjgo.v7.i12.411.
Pancreatic surgery for malignancy is recognized as challenging for the surgeons and risky for the patients due to consistent perioperative morbidity and mortality. Furthermore, the oncological long-term results are largely disappointing, even for those patients who experience an uneventfully hospital stay. Nevertheless, surgery still remains the cornerstone of a multidisciplinary treatment for pancreatic cancer. In order to maximize the benefits of surgery, the advent of both laparoscopy and robotics has led many surgeons to treat pancreatic cancers with these new methodologies. The reduction of postoperative complications, length of hospital stay and pain, together with a shorter interval between surgery and the beginning of adjuvant chemotherapy, represent the potential advantages over conventional surgery. Lastly, a better cosmetic result, although not crucial in any cancerous patient, could also play a role by improving overall well-being and patient self-perception. The laparoscopic approach to pancreatic surgery is, however, difficult in inexperienced hands and requires a dedicated training in both advanced laparoscopy and pancreatic surgery. The recent large diffusion of the da Vinci(®) robotic platform seems to facilitate many of the technical maneuvers, such as anastomotic biliary and pancreatic reconstructions, accurate lymphadenectomy, and vascular sutures. The two main pancreatic operations, distal pancreatectomy and pancreaticoduodenectomy, are approachable by a minimally invasive path, but more limited interventions such as enucleation are also feasible. Nevertheless, a word of caution should be taken into account when considering the increasing costs of these newest technologies because the main concerns regarding these are the maintenance of all oncological standards and the lack of long-term follow-up. The purpose of this review is to examine the evidence for the use of minimally invasive surgery in pancreatic cancer (and less aggressive tumors), with particular attention to the oncological results and widespread reproducibility of each technique.
由于围手术期发病率和死亡率持续存在,胰腺癌手术对外科医生来说具有挑战性,对患者来说风险很大。此外,即使对于那些住院过程顺利的患者,肿瘤学长期结果也大多令人失望。然而,手术仍然是胰腺癌多学科治疗的基石。为了最大限度地提高手术效益,腹腔镜和机器人技术的出现促使许多外科医生采用这些新方法治疗胰腺癌。与传统手术相比,微创手术具有减少术后并发症、缩短住院时间和疼痛,以及缩短手术与辅助化疗开始之间的间隔等潜在优势。最后,更好的美容效果虽然对任何癌症患者来说都不是关键因素,但也可以通过改善整体健康状况和患者自我认知发挥作用。然而,腹腔镜胰腺癌手术对于经验不足的医生来说难度较大,需要在高级腹腔镜手术和胰腺癌手术方面进行专门培训。最近达芬奇(®)机器人平台的广泛应用似乎便于进行许多技术操作,如胆胰吻合重建、精确的淋巴结清扫和血管缝合。两种主要的胰腺手术,即胰体尾切除术和胰十二指肠切除术,都可以通过微创途径进行,一些更有限的手术如肿瘤剜除术也可行。然而,在考虑这些最新技术成本不断增加的情况时应谨慎,因为主要担忧在于能否维持所有肿瘤学标准以及缺乏长期随访。本综述的目的是研究在胰腺癌(以及侵袭性较小的肿瘤)中使用微创手术的证据,特别关注每种技术的肿瘤学结果和广泛的可重复性。